|
|
|
Insider
Information: |
Baker Julian |
Relationship: |
|
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
33 |
|
Direct
Shares |
1,028,565 |
|
Indirect Shares
|
243,774,473 |
|
|
Direct
Value |
$74,412,006 |
|
|
Indirect Value
|
$16,676,232,797 |
|
|
Total
Shares |
244,803,038 |
|
|
Total
Value |
$16,750,644,803 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
46
|
7
|
Stock
price went up :
|
23
|
7
|
Stock
price went down : |
23
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
7.0
|
Percentage
Gain/Loss : |
11.8%
|
80.1%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Synageva BioPharma Corp |
GEVA |
10% Owner |
2003-09-26 |
0 |
2011-11-02 |
144,082 |
Premium* |
|
Innoviva Inc |
INVA |
Director |
2005-12-13 |
0 |
2004-10-04 |
33,839 |
Premium* |
|
Ardea Biosciences Inc |
RDEA |
Director, 10% Owner |
2004-10-13 |
0 |
2011-06-30 |
4,045,398 |
Premium* |
|
Incyte Corp |
INCY |
|
2024-05-07 |
559,963 |
2024-05-07 |
33,496,391 |
Premium* |
|
Genomic Health Inc |
GHDX |
Director, 10% Owner |
2019-08-29 |
0 |
2019-08-29 |
9,262,659 |
Premium* |
|
Allos Therapeutics Inc |
ALTH |
10% Owner |
2009-01-23 |
0 |
2009-01-23 |
2,258 |
Premium* |
|
Viropharma Inc |
VPHM |
10% Owner |
|
0 |
2011-12-14 |
9,840,469 |
Premium* |
|
Heron Therapeutics Inc |
HRTX |
10% Owner |
|
0 |
2009-10-19 |
5,264,782 |
Premium* |
|
Diadexus Inc |
DDXS |
10% Owner |
|
0 |
2012-01-27 |
0 |
Premium* |
|
Pharmacyclics Inc |
PCYC |
10% Owner |
2011-08-22 |
0 |
2012-02-10 |
557,211 |
Premium* |
|
XOMA Corporation |
XOMA |
Former 10% owner |
|
0 |
2015-07-22 |
90,538 |
Premium* |
|
Ocera Therapeutics Inc |
OCRX |
10% Owner |
2012-03-12 |
0 |
2012-03-14 |
3,540,015 |
Premium* |
|
Neurogene |
NGNE |
Director |
2020-07-07 |
4,520 |
2020-07-07 |
3,501,691 |
Premium* |
|
Acadia Pharmaceuticals Inc |
ACAD |
Director, 10% Owner |
2021-06-22 |
205,752 |
2021-06-22 |
38,452,877 |
Premium* |
|
Invitae Corp |
NVTA |
10% Owner |
2018-03-28 |
0 |
2018-03-28 |
7,553,553 |
Premium* |
|
Aceragen, Inc |
ACGN |
10% Owner |
2019-07-01 |
43,858 |
2019-07-01 |
4,290,995 |
Premium* |
|
Rhythm Pharmaceuticals, Inc. |
RYTM |
Former 10% owner |
2017-10-05 |
0 |
2017-10-05 |
1,878,242 |
Premium* |
|
Mirati Therapeutics, Inc. |
MRTX |
10% Owner |
2017-11-08 |
274 |
2017-11-08 |
35,999 |
Premium* |
|
Bellicum Pharmaceuticals, Inc |
BLCM |
10% Owner |
2018-01-17 |
0 |
2018-01-19 |
58,131 |
Premium* |
|
Beigene Ltd |
BGNE |
Director, 10% Owner |
2021-06-16 |
20,838 |
2021-06-16 |
11,703,086 |
Premium* |
|
Seagen Inc |
SGEN |
Director, 10% Owner |
2021-05-14 |
46,557 |
2021-05-14 |
43,309,073 |
Premium* |
|
Alexion Pharmaceuticals Inc |
ALXN |
Director |
2020-05-14 |
131,963 |
2020-05-14 |
7,940,623 |
Premium* |
|
Kiniksa Pharmaceuticals, Ltd. |
KNSA |
Director, 10% Owner |
2019-06-06 |
14,840 |
2019-06-06 |
2,700,597 |
Premium* |
|
Kodiak Sciences Inc. |
KOD |
Director, 10% Owner |
2018-10-09 |
0 |
2021-09-30 |
13,526,726 |
Premium* |
|
Atreca Inc |
BCEL |
10% Owner |
2019-06-24 |
0 |
2019-06-24 |
3,223,030 |
Premium* |
|
Igm Biosciences, Inc. |
IGMS |
Director, 10% Owner |
2019-09-20 |
0 |
2021-01-27 |
2,895,306 |
Premium* |
|
Prelude Therapeutics Inc |
PRLD |
Director, 10% Owner |
|
0 |
2021-01-27 |
9,252,951 |
Premium* |
|
DBV Technologies SA |
DBVT |
Director, 10% Owner |
|
0 |
2021-01-01 |
4,286,038 |
Premium* |
|
Talis Biomedical Corp |
TLIS |
Director, 10% Owner |
|
0 |
2021-02-17 |
7,003,766 |
Premium* |
|
Aeglea Biotherapeutics, Inc. |
AGLE |
Director |
|
0 |
2021-02-23 |
3,410,106 |
Premium* |
|
Tscan Therapeutics, Inc. |
TCRX |
Director |
2021-07-20 |
0 |
2021-07-20 |
1,320,302 |
Premium* |
|
Entrada Therapeutics, Inc. |
TRDA |
10% Owner |
|
0 |
2021-12-14 |
4,704,419 |
Premium* |
|
Bicycle Therapeutics Ltd |
BCYC |
|
|
0 |
2024-04-18 |
6,449,320 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
496 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 12 of 20
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
INCY |
Incyte Corp |
Director |
|
2007-12-17 |
4 |
B |
$10.60 |
$20,915 |
I/I |
1,974 |
102,036 |
2.17 |
- |
|
INCY |
Incyte Corp |
Director |
|
2007-12-17 |
4 |
B |
$10.60 |
$1,001,945 |
I/I |
94,565 |
4,133,664 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2007-12-17 |
4 |
B |
$10.60 |
$2,734 |
I/I |
258 |
278,513 |
2.17 |
- |
|
NGNE |
Neurogene |
10% Owner |
|
2016-01-22 |
4 |
B |
$10.60 |
$559,810 |
I/I |
52,202 |
6,422,989 |
1.5 |
- |
|
INCY |
Incyte Corp |
Director |
|
2007-12-19 |
4 |
B |
$10.61 |
$19,752 |
I/I |
1,862 |
105,022 |
2.17 |
- |
|
INCY |
Incyte Corp |
Director |
|
2007-12-19 |
4 |
B |
$10.61 |
$2,578 |
I/I |
243 |
278,903 |
2.17 |
- |
|
INCY |
Incyte Corp |
Director |
|
2007-12-19 |
4 |
B |
$10.61 |
$373,755 |
I/I |
35,234 |
2,592,218 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2007-12-19 |
4 |
B |
$10.61 |
$30,063 |
I/I |
2,834 |
94,961 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2007-12-19 |
4 |
B |
$10.61 |
$946,195 |
I/I |
89,198 |
4,276,686 |
2.25 |
- |
|
NGNE |
Neurogene |
10% Owner |
|
2016-01-26 |
4 |
B |
$10.80 |
$839,524 |
I/I |
77,639 |
6,502,773 |
1.5 |
- |
|
NGNE |
Neurogene |
10% Owner |
|
2016-01-25 |
4 |
B |
$10.98 |
$121,576 |
I/I |
10,945 |
6,432,847 |
1.5 |
- |
|
RDEA |
Ardea Biosciences Inc |
10% Owner |
|
2008-12-19 |
4 |
B |
$11.14 |
$6,563,343 |
I/I |
589,169 |
3,193,943 |
1.5 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2005-10-04 |
4 |
B |
$12.00 |
$1,635,792 |
I/I |
136,316 |
252,529 |
2.25 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2005-10-04 |
4 |
B |
$12.00 |
$464,208 |
I/I |
38,684 |
181,478 |
2.25 |
- |
|
PCYC |
Pharmacyclics Inc |
10% Owner |
|
2011-11-21 |
4 |
B |
$12.01 |
$33,526 |
I/I |
2,778 |
155,432 |
1.5 |
- |
|
PCYC |
Pharmacyclics Inc |
10% Owner |
|
2011-11-21 |
4 |
B |
$12.01 |
$846,886 |
I/I |
70,173 |
6,965,853 |
1.5 |
- |
|
NGNE |
Neurogene |
10% Owner |
|
2016-09-20 |
4 |
B |
$12.25 |
$34,110,452 |
I/I |
2,783,605 |
1,131,625 |
1.5 |
- |
|
PCYC |
Pharmacyclics Inc |
10% Owner |
|
2011-11-22 |
4 |
B |
$12.51 |
$1,011,570 |
I/I |
79,131 |
7,044,984 |
1.5 |
- |
|
PCYC |
Pharmacyclics Inc |
10% Owner |
|
2011-11-22 |
4 |
B |
$12.51 |
$44,640 |
I/I |
3,492 |
158,924 |
1.5 |
- |
|
VPHM |
Viropharma Inc |
10% Owner |
|
2010-04-28 |
4 |
B |
$12.70 |
$7,638,151 |
I/I |
600,619 |
7,735,006 |
1.5 |
- |
|
VPHM |
Viropharma Inc |
10% Owner |
|
2010-04-30 |
4 |
B |
$12.76 |
$5,503,790 |
I/I |
431,154 |
9,080,664 |
1.5 |
- |
|
PCYC |
Pharmacyclics Inc |
10% Owner |
|
2011-11-23 |
4 |
B |
$12.76 |
$9,532 |
I/I |
747 |
159,671 |
1.5 |
- |
|
PCYC |
Pharmacyclics Inc |
10% Owner |
|
2011-11-23 |
4 |
B |
$12.76 |
$1,189,165 |
I/I |
93,194 |
7,138,178 |
1.5 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2020-04-23 |
4 |
OE |
$12.76 |
$446,600 |
I/I |
35,000 |
45,860,149 |
0 |
- |
|
PRLD |
Prelude Therapeutics Inc |
Director |
|
2021-01-27 |
4 |
OE |
$12.85 |
$133,332 |
I/I |
10,376 |
9,252,951 |
0 |
- |
|
496 Records found
|
|
Page 12 of 20 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|